New drug combo aims to keep leukemia at bay after transplant
NCT ID NCT07199855
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tests whether two drugs, blinatumomab and venetoclax, can help prevent cancer from coming back in people with a high-risk type of B-cell leukemia after a stem cell transplant. About 24 adults aged 14 to 65 will receive the combination as maintenance therapy. The main goal is to see how many remain cancer-free for two years after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.